Abbott Laboratories (Pakistan) Past Earnings Performance
Past criteria checks 0/6
Abbott Laboratories (Pakistan)'s earnings have been declining at an average annual rate of -3.9%, while the Pharmaceuticals industry saw earnings growing at 4.1% annually. Revenues have been growing at an average rate of 14.1% per year. Abbott Laboratories (Pakistan)'s return on equity is 1.4%, and it has net margins of 0.5%.
Key information
-3.9%
Earnings growth rate
-3.9%
EPS growth rate
Pharmaceuticals Industry Growth | 20.2% |
Revenue growth rate | 14.1% |
Return on equity | 1.4% |
Net Margin | 0.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Abbott Laboratories (Pakistan) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 55,475 | 262 | 8,989 | 0 |
30 Sep 23 | 53,531 | -353 | 8,691 | 0 |
30 Jun 23 | 51,820 | 425 | 8,441 | 0 |
31 Mar 23 | 51,292 | 1,343 | 8,125 | 0 |
31 Dec 22 | 49,258 | 3,004 | 7,835 | 0 |
30 Sep 22 | 48,074 | 4,040 | 7,903 | 0 |
30 Jun 22 | 46,452 | 4,465 | 7,744 | 0 |
31 Mar 22 | 44,450 | 5,966 | 7,426 | 0 |
31 Dec 21 | 42,570 | 5,967 | 7,232 | 0 |
30 Sep 21 | 41,759 | 5,922 | 6,809 | 0 |
30 Jun 21 | 39,548 | 5,697 | 6,385 | 0 |
31 Mar 21 | 37,113 | 5,115 | 5,926 | 0 |
31 Dec 20 | 35,283 | 4,535 | 5,516 | 0 |
30 Sep 20 | 32,847 | 3,633 | 5,484 | 0 |
30 Jun 20 | 31,384 | 2,914 | 5,392 | 0 |
31 Mar 20 | 31,002 | 1,835 | 5,483 | 0 |
31 Dec 19 | 30,156 | 1,300 | 5,746 | 0 |
30 Sep 19 | 30,405 | 1,396 | 5,556 | 0 |
30 Jun 19 | 31,247 | 1,948 | 5,420 | 0 |
31 Mar 19 | 30,603 | 2,402 | 5,392 | 0 |
31 Dec 18 | 29,719 | 2,694 | 5,070 | 0 |
30 Sep 18 | 29,023 | 3,487 | 4,875 | 0 |
30 Jun 18 | 27,808 | 3,780 | 4,645 | 0 |
31 Mar 18 | 27,026 | 4,121 | 4,388 | 0 |
31 Dec 17 | 26,088 | 4,205 | 4,043 | 0 |
30 Sep 17 | 25,258 | 3,965 | 4,056 | 0 |
30 Jun 17 | 24,479 | 3,999 | 3,888 | 0 |
31 Mar 17 | 23,897 | 4,005 | 3,766 | 0 |
31 Dec 16 | 23,388 | 4,022 | 3,678 | 0 |
30 Sep 16 | 22,687 | 4,021 | 3,463 | 0 |
30 Jun 16 | 22,335 | 3,816 | 3,494 | 0 |
31 Mar 16 | 21,789 | 3,746 | 3,370 | 0 |
31 Dec 15 | 21,170 | 3,587 | 3,233 | 0 |
30 Sep 15 | 20,923 | 3,219 | 3,464 | 0 |
30 Jun 15 | 20,161 | 2,961 | 3,298 | 0 |
31 Mar 15 | 19,511 | 2,749 | 3,321 | 0 |
31 Dec 14 | 19,692 | 2,816 | 3,306 | 0 |
30 Sep 14 | 18,870 | 2,784 | 3,029 | 0 |
30 Jun 14 | 18,328 | 2,717 | 3,012 | 0 |
31 Mar 14 | 17,825 | 2,700 | 2,926 | 0 |
31 Dec 13 | 17,217 | 2,529 | 2,821 | 0 |
30 Sep 13 | 16,609 | 2,335 | 2,765 | 0 |
30 Jun 13 | 16,009 | 2,210 | 2,659 | 0 |
Quality Earnings: ABOT has a high level of non-cash earnings.
Growing Profit Margin: ABOT's current net profit margins (0.5%) are lower than last year (6.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABOT's earnings have declined by 3.9% per year over the past 5 years.
Accelerating Growth: ABOT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ABOT had negative earnings growth (-91.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-3.3%).
Return on Equity
High ROE: ABOT's Return on Equity (1.4%) is considered low.